ICYMI: Research Roundup from AIDS 2024
Topics
Summary:
A brief roundup of key topics of HIV.gov’s coverage of AIDS 2024, including HIV prevention, cure research, and more.
At the recent International AIDS Society’s AIDS 2024 conference in Munich, HIV.gov spoke with colleagues about the latest research presented at the event. In case you missed any of our video conversations, here’s a roundup of key topics that you can share.
To learn about the latest research on:
- HIV PrEP – Watch our conversations with NIH’S Dr. Jeanne Marrazzo, who discussed results of the PURPOSE 1 study of lenacapavirExit Disclaimer for twice-yearly PrEP and new evidence on cabotegravir PrEP every two months (CAB-LA) in pregnancy; and NIH’s Dr. Carl Dieffenbach, who reviewed findings about HIV testing while on CAB-LA. Read these NIH news releases on CAB-LA in pregnancy and HIV testing while on CAB-LA.
- Doxy PrEP – View our conversation with Dr. Troy Grennan, physician lead for the Provincial HIV/STI Program, British Columbia Centre for Disease Control and Clinical Associate Professor, University of British Columbia, about research findings he shared on the potential of doxycycline as pre-exposure prophylaxis for STIs, or Doxy PrEP, which is not yet available.
- HIV prevention – See this conversation with Dr. Dieffenbach, who summarized a plenary on HIV prevention, and this discussion of the current HIV Prevention Trials Network 103 study of long-acting lenacapavir for HIV PrEP in people who inject drugs.
- HIV cure research – Watch Dr. Dieffenbach discuss the case report of a unique patient, as well as research on the use of HIV broadly neutralizing antibodies.
- Community-informed research – See this conversation with Dr. Marrazzo; and our discussion with PACHA Global Subcommittee Co-Chairs Jennifer Kates and Patrick Sullivan about their reflections on AIDS 2024.
We also shared a preview of the conference with Dr. Dieffenbach, who highlighted studies related to long-acting PrEP. You can find all of our videos to watch and share on this YouTube playlistExit Disclaimer, HIV.gov’s Facebook pageExit Disclaimer, Twitter/XExit Disclaimer, and the HHS Office of Infectious Disease and HIV/AIDS Policy’s LinkedIn pageExit Disclaimer.